| IVP 0.082 256.52% | OCG 0.0118 4.42% | SOXS 2.28 0.48% | SEGG 0.9267 79.91% | ZSL 2.82 -14.80% | MTEN 0.0353 4.75% | SLV 84.56 7.58% | SAFX 0.1373 -17.74% | NVDA 183.14 -1.44% | INTC 48.72 3.02% | ASST 1.03 6.19% | TZA 6.16 -1.99% | TQQQ 53.83 -3.18% | JTAI 0.4546 13.65% | DVLT 0.7182 -10.33% | SPY 690.36 -0.49% | PSTV 0.2904 -38.23% | BBAI 6.26 2.79% | IBIT 55.44 3.49% | ONDS 13.56 -2.38% | MSTX 5.2 7.22% | PLUG 2.35 3.07% | ROLR 18.89 436.65% | XLE 48.06 2.26% | QQQ 619.55 -1.07% | TSLL 18.07 -3.58% | BAC 52.48 -3.78% | SOXL 55.38 -1.23% | ASBP 0.0587 -26.44% | BMNR 32.68 4.68% | BITO 13.56 3.39% | TSLS 5.19 1.76% | DUST 5.8 -0.68% | AAL 15.14 -1.37% | BITF 2.94 -5.47% | FNGD 5.51 5.15% | DNN 3.49 4.33% | ACHR 8.91 5.19% | CLSK 13.34 6.29% | F 13.835 -1.04% | JDST 2.11 -0.71% | XLF 54.15 -0.15% | CRML 17.925 32.58% | BEEM 1.87 5.65% | ETHA 25.59 5.66% | TSLA 439.2 -1.79% | OPEN 6.64 -1.92% | MARA 11.11 1.46% | PBR 12.66 2.93% | SIDU 3.75 20.58%

Market Downturn Hits Various Sectors Hard

In the recent market downturn, several companies have experienced significant price declines, reflecting various underlying challenges and market sentiments. Among the top losers, Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a dramatic drop of approximately 49.5%, with its price falling to $1.01. This biotechnology firm, focused on developing cancer treatments, has faced volatility, with its stock price fluctuating from a high of $88 to a low of $0.91 over the past year. Salarius recently announced a public offering to raise approximately $7 million, which includes over 2.5 million shares of common stock and pre-funded warrants for an additional 2.1 million shares. This move aims to bolster its financial position amidst market challenges.

Vor Biopharma Inc. (NASDAQ:VOR), engaged in developing treatments for cancer patients, saw its stock price halve, decreasing by 47.77% to $9.82. The company, which has been working on engineered hematopoietic stem cell therapies, has experienced a significant market correction from its yearly high of $65.8. Despite this, Vor Biopharma has successfully secured a $100 million offering following positive results from a kidney disease trial, pricing 10 million shares at $10 each in this underwritten public offering.

Outset Medical, Inc. (NASDAQ:OM), a medical technology company that develops innovative hemodialysis systems, witnessed a 46.89% decline in its stock price to $6.40. This decrease reflects broader challenges within the healthcare sector, particularly for companies in the medical device industry. The pre-market session saw declines in major stocks, including Outset Medical, as highlighted by the S&P 500 futures' decrease of around 0.2%.

Epsium Enterprise Limited (EPSM), which engages in the import trading and wholesale of alcoholic beverages, saw its stock price decrease by 43.1% to $3.27. The company, with a diverse portfolio of wines and spirits, has faced market adjustments, with its stock price ranging from a high of $155 to a low of $2.62 over the past year. Epsium has responded to unusual trading activity in its shares by issuing a statement addressing this recent market behavior.

These significant price movements highlight the volatility and challenges faced by companies across various sectors. Market participants will closely monitor these companies for any signs of recovery or further adjustments in their stock prices.

Published on: November 11, 2025